RE:RE:RE:RE:So are we on to the next big thing?I don't know. First it depends on a possible correlation between efficacy on human and on a PDX model, ans also, efficacy on a PDX model and a xenograft model out of commercial cancer cells. Only after that will the validity of the model, for us, outside observers could become a question. But if Thera goes that way, i guess it's because they will think that the PDX approach is valid. One thing is sure, cells from the patients cultured a few times in the labs before grafting are in theory a better model than using commercial cancer cells cultured thousands of times.
SPCEO1 wrote: JFM1330 - does the claim made by Charles River seem legit and does it influence you to think any differently about the riskiness of the jump from success in nude mice to humans? Did it make you think the possibility of success in the phase 1a is any higher than you previously thought?
jfm1330 wrote: Remember that Marsolais said that they will publish a paper in 2022 based on patient derived xenograft (PDX). Which is grafting cancer cells from the patient to a nude mouse and test efficacy against a given drug. Charles River Labs are offering this service and they state the following:
Establishing xenograft tumor models from patient-derived tumor tissue (PDTT) at low passage is believed to conserve original tumor characteristics such as heterogeneous histology, clinical biomolecular signature, malignant phenotypes and genotypes, tumor architecture, and tumor vasculature. Based on this prevalent hypothesis, patient-derived xenografts are believed to offer relevant predictive insights into clinical outcomes when evaluating the efficacy of novel cancer therapies. So now that Thera will be testing TH1902 on humans with biopsies to select sortilin overexpression, they could also test these cancers from real patients using PDX. They would see if there is a correlation between efficacy on the mouse and and on real patients. It would also potentially help to select future drugs to add to TH19P01 in a future PDC to develop on human clinical trials. That's one exciting avenue we know they are exploring right now.
Wino115 wrote: Not at all. This is all about TH1902 suceeding, getting that high dosage, moving in to the rest of the Phase 1. We're talking about the other things you could do AFTER they get TH1902 further down the road toward commercialization and cranking in the revenues. I'm sure that will take all they can muster at this point if we see it move fast.
THe science team here has made mention they've heard little "clues" PL or Marsolais drop that make it sound like they are already playing around with the next ideas for the peptide. Maybe it's the rubicin version, the SN-38 version, some combo, or a TKI for hematological cancers. If you have a platform, you should have guys in the lab playing around with everything those brilliant minds can come up with! It's cheap experimenting and you may see something amazing or useless. We're speculating around that kind of stuff, not moving on to something else. We still need to see POC and efficacy afterall.
Bucknelly21 wrote: Are we moving on to the best thing that thera is going to look for? Sounds like some are getting over cancer already lol